| Literature DB >> 28193516 |
Josep Vidal1, Ricard Corcelles2, Amanda Jiménez3, Lílliam Flores4, Antonio M Lacy5.
Abstract
Metabolic and bariatric surgery (MBS) leads to weight loss in obese individuals and reduces comorbidities such as type 2 diabetes. MBS is superior to medical therapy in reducing hyperglycemia in persons with type 2 diabetes, and has been associated with reduced mortality and incidences of cardiovascular events and cancer in obese individuals. New guidelines have been proposed for the use of MBS in persons with type 2 diabetes. We review the use of MBS as a treatment for obesity and obesity-related conditions and, based on recent evidence, propose that health care systems make the appropriate changes to increase accessibility for eligible patients.Entities:
Keywords: Bariatric Surgery; Metabolic Surgery; Mortality; Type 2 Diabetes; Weight Loss
Mesh:
Substances:
Year: 2017 PMID: 28193516 DOI: 10.1053/j.gastro.2017.01.051
Source DB: PubMed Journal: Gastroenterology ISSN: 0016-5085 Impact factor: 22.682